Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips

First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips

Feb 28, 2020
|
staff reporter

NEW YORK – First Analysis Securities on Thursday upgraded NeoGenomics' shares to Strong Buy from a prior Outperform rating after the firm's shares fell 8 percent following its Q4 earnings report and outlook.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

What's Popular?

In Business News

  1. Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

  2. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  3. JumpCode Genomics Emerges From Stealth Mode With CRISPR-Based Library Prep Kits

    Premium

  4. CRISPR-Chip Maker Cardea Bio Raises $7.5M in First Close of Series A2 Financing Round

  5. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.